Nurix Therapeutics posts $549.8 million Q3 net income on Roche license revenue
Nurix Therapeutics reported results for the fiscal quarter ended August 31, 2026. Total revenue rose to $673.1 million from $7.9 million a year earlier, mainly from $653.2 million of license revenue tied to the Roche collaboration, and the company reported net income of $549.8 million, or $4.73 per diluted share, compared with a net loss of $86.4 million a year earlier. Because most of the revenue came from a single license payment, the filing's profit figures are driven by that item rather than by recurring sales.
Key points
- Total revenue was $673.1 million, versus $7.9 million a year earlier, including $653.2 million of Roche license revenue.
- Net income was $549.8 million, or $4.73 per diluted share, versus a net loss of $86.4 million, or $1.03 per share, a year earlier.
- General and administrative expenses rose to $34.4 million from $13.2 million, mainly due to one-time Roche transaction costs.
- Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, versus $592.9 million on November 30, 2025.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.